Stifel analyst David Grossman reiterated a Buy rating and $320 price target on Veeva (VEEV) after the company said that Bristol Myers (BMY) committed to Veeva Vault CRM, marking yet another top-20 Pharma customer formally committing to the platform, joining the likes of Merck (MRK), Novo Nordisk (NVO), GSK (GSK), Bayer (BAYRY), and Astellas (ALPMY). The firm noted that the company also got a verbal commitment from Gilead Sciences (GILD). While Monday’s announcement is not incremental, the formal announcement is a reminder of Veeva’s progress in converting the IB to the new platform, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva says Bristol Myers commits to Veeva Vault CRM
- Aquestive, Veeva, Oklo, BioMarin, TKO: Trending by Analysts
- Veeva Systems: Strategic Positioning and Growth Potential Justify Buy Rating
- Veeva receives another Top 20 Vault CRM commitment, says Raymond James
- Veeva says Gilead commits to Veeva Vault CRM